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Abstract: ∆9-Tetrahydrocannabinol (THC) has complex effects on the cardiovascular system. We 
aimed to systematically review studies of THC and haemodynamic alterations. PubMed, Medline, 
and EMBASE were searched for relevant studies. Changes in blood pressure (BP), heart rate (HR), 
and blood flow (BF) were analysed using the Cochrane Review Manager Software. Thirty-one 
studies met the eligibility criteria. Fourteen publications assessed BP (number, n = 541), 22 HR (n = 
567), and 3 BF (n = 45). Acute THC dosing reduced BP and HR in anaesthetised animals (BP, mean 
difference (MD) −19.7 mmHg, p < 0.00001; HR, MD −53.49 bpm, p < 0.00001), conscious animals (BP, 
MD −12.3 mmHg, p = 0.0007; HR, MD −30.05 bpm, p < 0.00001), and animal models of stress or 
hypertension (BP, MD −61.37 mmHg, p = 0.03) and increased cerebral BF in murine stroke models 
(MD 32.35%, p < 0.00001). Chronic dosing increased BF in large arteries in anaesthetised animals 
(MD 21.95 mL/min, p = 0.05) and reduced BP in models of stress or hypertension (MD −22.09 
mmHg, p < 0.00001). In humans, acute administration increased HR (MD 8.16 bpm, p < 0.00001). 
THC acts differently according to species and experimental conditions, causing bradycardia, 
hypotension and increased BF in animals; and causing increased HR in humans. Data is limited, 
and further studies assessing THC-induced haemodynamic changes in humans should be 
considered. 
Keywords: ∆9-Tetrahydrocannabinol; THC; cardiovascular system; blood pressure; heart rate;  
blood flow 
 
1. Introduction 
∆9-Tetrahydrocannabinol (THC) is the most abundant and widely studied phytocannabinoid, 
first discovered in 1964 [1]. THC is a partial agonist of both cannabinoid receptors CB1 and CB2 and 
other targets including G protein-coupled receptors GPR55 and GPR18 [2–4]. THC possesses 
interesting therapeutic potential as an antiemetic, appetite stimulant, and analgesic, and for the 
treatment of glaucoma, epilepsy, Parkinson`s disease, and multiple sclerosis [5–7]. THC has been 
shown to be effective against refractory nausea and vomiting in cancer patients undergoing 
chemotherapy [8]. However, its use as a therapeutic agent is limited by its recognised psychogenic 
side effects including hallucinations, euphoria, dizziness, mood changes, nausea, and fatigue [8–10]. 
THC has numerous cardiovascular effects in animals and humans. In vitro studies have shown 
that THC causes endothelium-independent vasorelaxation of rabbit superior mesenteric arteries [11] 
and vasorelaxation of the rat mesenteric artery through sensory nerves via a CB1 and CB2 
receptor-independent mechanism [12]. Other studies have found THC to activate a G 
protein-coupled receptor, inhibit calcium channels, and activate potassium channels in the rat 
mesenteric vasculature [13] and to cause endothelium-dependent and time-dependent 
vasorelaxation in the rat aorta [14,15]. In contrast, other studies have shown that THC causes 
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vasoconstriction in guinea pig pulmonary arteries [16], rat mesenteric arteries and aorta [14,17], and 
rabbit ear arteries [18]. 
In vivo studies have reported different haemodynamic responses post-THC. An acute 
administration of THC caused hypotension and bradycardia in anesthetised dogs (intravenously; 
i.v.), conscious bats (intraperitoneal; i.p.), and humans (oral) [19–21]. In contrast, tachycardia and 
hypertension were reported in rats after i.p. administration of THC [22,23]. More complex effects on 
BP were induced by THC in anaesthetised rats [24]. The available evidence to date suggests that 
THC alters the haemodynamics in animals and humans, albeit with conflicting results variable with 
species, route of administration, and experimental conditions. Therefore, the aim this study was to 
systematically review and meta-analyse the in vivo literature assessing the effects of THC on the 
cardiovascular system in all species under different conditions. 
2. Results 
From the initial 2,743 search results, 1,935 relevant publications were identified and evaluated 
from three databases (Medline, EMBASE, and PubMed). Of these, 30 articles met the inclusion 
criteria and 1 article was added manually (Figure 1). A summary of the data extracted from the 
included studies is shown in Table 1. 
 
Figure 1. Flow chart for study retrieval and selection.  
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Table 1. Summary of the included studies divided according to the experimental conditions. 
Author & 
Year 
Study Description 
Species, Model 
(Anaesthetic & Route) 
Sample 
Size 
THC Dose 
THC 
Route 
Time of THC 
Administration 
Time of Haemodynamic 
Measurements 
Basal 
Parameters * 
Outcomes and Comments 
Anaesthetised animals 
Cavero 1972 
[25] 
Investigate the 
haemodynamic effects 
of THC 
Dogs 
Anaesthetised 
(pentobarbital, iv) 
11 2.5 mg/kg i.v. Post-anaesthesia 
Continues for 30 m 
post-drug 
- 
THC altered distribution of regional 
BF, and reduced HR and BP. 
Cavero 1973a 
[26] 
Investigate the 
haemodynamic effects 
of THC 
Dogs 
Anaesthetised 
(pentobarbital, iv) 
23 
39 µg/kg–
2.5 mg/kg 
i.v. Post-anaesthesia 
Continues for 2 h 
post-drug 
C: HR:169, 
BP:91.7; 
T: HR:165.7, 
BP:93.5 
THC caused reduction in HR and BP 
mediated via central nervous system. 
Cavero 1973b 
[27] 
Characterise the 
mechanism of action 
of THC on HR 
Dogs 
Anaesthetised 
(pentobarbital, iv) 
29 
39 µg/kg–5 
mg/kg 
i.v. Post-anaesthesia 
Continues for 140 m 
post-drug 
- 
THC induced reduction in HR through 
alteration of autonomic innervation to 
myocardium. 
Cavero 1974 
[19] 
Investigate the effect 
of THC on venous 
return 
Dogs (heart bypass) 
Anaesthetised 
(dibucaine, spinal) 
8 2.5 mg/kg i.v. Post-anaesthesia 
Pre-drug and continues 
for 30 m post-drug 
C: HR:156, 
BP:85.8; 
T: HR:147, 
BP:85. 
THC caused reduction in HR and BP, 
and reduced venous return. 
Daskalopoul
os 1975 [28] 
Investigate the 
mechanism of THC on 
CV system 
Cats 
Anaesthetised 
(urethane, iv) 
40 
30–300 
µg/kg 
i.v. Post-anaesthesia 20 m post-drug - 
THC reduced HR and BP mediated via 
central nervous system. 
Adams 1976 
[29] 
Examined the CV 
effects of THC 
Rats 
Anaesthetised 
(urethane, ip) 
72 
0.1–3 
mg/kg 
i.v. Post-anaesthesia 
Continues for 30min 
post-drug 
C: HR:316.2, 
BP:76.2; 
T: HR:314.8, 
BP:73.5. 
THC caused reduction in HR and 
biphasic BP response (↑ BP followed by 
↓ BP), suggesting that THC depressed 
CV reflex functions. 
Jandhyala 
1976 [30] 
Evaluated possible 
interaction with THC 
on HR 
Dogs 
Anaesthetised 
(pentobarbital) 
12 1 mg/kg s.c. 
Twice/day for 7 
days 
Pre-anaesthesia 
On the 7th day 
post-anaesthesia 
- 
Chronic THC antagonised the elevation 
in HR induced by the anaesthetic agent 
via vagal stimulation. 
Jandhyala 
1977 [31] 
Determined chronic 
administration of 
THC on CV function 
Dogs 
Anaesthetised 
(pentobarbital) 
16 1 mg/kg s.c. 
Twice/day for 7 
days 
Pre-anaesthesia 
On the 7th day 
post-anaesthesia 
- 
Chronic THC had no effect on 
haemodynamics. 
Jandhyala 
1978 [32] 
Investigated 
prolonged THC 
effects on CV system 
Dogs 
Anaesthetised 
(pentobarbital) 
16 2 mg/kg s.c. 
Single dose per 
day for 35 days 
On the 35th day 
post-anaesthesia 
- 
Chronic THC increased BF in femoral 
and mesenteric arteries with no effect 
on HR or BP. 
McConnell 
1978 [33] 
Examined the effects 
of THC on salivary 
flow 
Cats 
Anaesthetised (urethane 
& pentobarbital, ip) 
20  
0.1–2 
mg/kg 
i.v. Post-anaesthesia 
Continues for 1 h 
post-drug 
- 
THC had no effect in stimulated 
salivary flow of cats. THC caused a 
reduction in HR and BP. 
Siqueira 1979 
[24] 
Clarify the triple BP 
response post-THC 
Rats 
Anaesthetised 
(urethane, ip) 
50 1–10 mg/kg i.v. Post-anaesthesia 
Continues for 70 m 
post-drug 
- 
THC induced triphasic BP response (↓ 
BP via vagal stimulation, then ↑ BP not 
dependent on sympathetic activity 
followed by ↓ BP due to central 
decrease in sympathetic tone). 
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Kawasaki 
1980 [23] 
Investigated the effect 
of THC on the CV 
system and behavior 
changes 
Rats 
Anaesthetised 
(urethane, ip) 
29  1–5 mg/kg i.v. Post-anaesthesia 
Continues for 70 m 
post-drug 
- 
THC induced CV effects (↓ HR and ↑ 
BP) through vagal activity, and 
influence behavior changes to brain 
stimulation. 
Schmeling 
1981 [34] 
Investigated the effect 
of THC on 
hypothalamus 
Cats 
Anaesthetised 
(urethane, ip) 
12 2 mg/kg i.v. Post-anaesthesia 
Continues for 30 m 
post-drug 
- 
THC produced significant reductions 
in HR and BP and attenuated the 
pressor response threshold suggesting 
that THC reduces sympathetic activity. 
Estrada 1987 
[35] 
Investigated the CV 
effects of THC 
Rats 
Anaesthetised 
(pentobarbital, ip) 
28 
0.078–5 
mg/kg 
i.v. Post-anaesthesia 3-12 min post-drug - 
THC produced adverse effects on the 
CV system (↓ HR and ↓ BP) 
Krowicki 
1999 [36] 
Investigated whether 
CB1 activation by 
THC inhibits gastric 
motor function 
Rats 
Anaesthetised 
(ketamine and xylazine) 
36 
0.02–2 
mg/kg 
i.v. Post-anaesthesia 
Continues for 10 m 
post-drug 
- 
THC decreased gastric motor function, 
HR, and BP via autonomic effects 
mediated by CB1. 
Conscious animals 
Kaymakcalan 
1974 [37] 
Investigated chronic 
effects of THC on HR 
Rats 
Conscious 
20 10 mg/kg s.c. 
Single dose per 
day for 16 days 
Hourly interval to 6 h on 
the 1st, 4th, 8th and 16th 
days 
- 
THC produced marked reduction in 
HR 
Borgen 1974 
[38] 
Examined possible 
interaction of CBD on 
THC effects 
Rabbits 
Conscious 
8 3 mg/kg i.v. Pre-test 
Pre-drug and hourly 
interval to 7 h post-drug 
C: HR:264; 
T: HR:276 
CBD reduced the hypothermic effect of 
THC and attenuated the depressant 
effects of THC on respiration, rectal 
temperature and HR 
Brown 1974 
[20] 
Investigated CV 
response to THC 
Bats 
Conscious 
12 
100 and 200 
mg/kg 
i.p. Pre-test 
Pre-drug and continues 
for 145 m post-drug 
C: HR:436, 
BP:101; 
T: HR:390, 
BP:114 
THC induced hypothermia and 
reduction in HR and BP. 
Osgood 1977 
[22] 
Investigated THC 
effects on HR  
Rats 
Conscious 
18 0.5 mg/kg i.p. Pre-test 
Continues for 30 m 
post-drug 
- 
THC had minimal effect on BP and 
caused an increase in HR, which may 
be related to central mediation release 
of epinephrine from adrenal gland. 
Kawasaki 
1980 [23] 
Investigated the 
effects of THC on the 
CV system and 
behavior changes  
Rats 
Conscious 
21 4–8 mg/kg i.p. Pre-test 
Continues for 2 h 
post-drug 
- 
THC induced CV effects (↓ HR and ↑ 
BP) through vagal activity, and 
influenced behavior changes to brain 
stimulation. 
Matsuzaki 
1987 [39] 
Examined the effects 
of THC on EEG, body 
temperature, and HR 
Monkeys 
Conscious 
6 
0.4–4 
mg/kg 
i.p. Pre-test 
Continues for 5 h 
post-drug 
- 
THC induced reduction in HR and 
hypothermia and induced responses of 
EGG along with behavioral depression 
and alertness. 
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Hayakawa 
2007a [40] 
Investigated CBD and 
THC effects on 
ischemic brain 
damage 
Stroke Mice 
Conscious 
17 10 mg/kg i.p. 
Pre-, 3 and 4 h 
post-occlusion, 
and 1 and 2 h 
post-reperfusion 
BP and HR: 
pre-reperfusion. CBF: 
continued 4 h 
post-occlusion and 1 
post-reperfusion 
- 
Pre and post-ischemic treatment with 
CBD induced neuroprotection, 
whereas only preischemic treatment 
with THC induced neuroprotection. 
THC increased CBF with no effects on 
BP or HR 
Hayakawa 
2007b [41] 
Explored the 
development of 
tolerance of THC and 
CBD neuroprotection 
Stroke Mice 
Conscious 
7 10 mg/kg i.p. 
Pre-occlusion and 
3 h 
post-occlusion. 
Single dose per 
day for 14 days 
During 4 h and on day 14 
post-occlusion 
- 
Repeated treatment with CBD, but not 
THC, induced neuroprotection with 
development of tolerance. THC 
increased CBF on day 1 only with no 
effects on BP or HR. 
Stress and hypertensive animal models 
Williams 
1973 [42] 
Studied the effects of 
THC on BP 
Rats 
Stress 
30 20 mg/kg s.c. 
Single dose per 
day for 4 days 
Pre-drug, 4 h, 48 and 96 h 
post-drug  
C: BP:128; 
T: BP:129 
THC reduced BP 
Birmingham 
1973 [43] 
Studies the effects of 
THC on BP 
Rats 
Hypertensive 
10 3 mg/kg i.p. 
Single dose per 
day for 7 days 
Hourly to 5 h for 7 days  - THC reduced BP 
Kosersky 
1978 [44] 
Examined the 
antihypertensive 
effects of THC 
Rats 
Hypertensive 
12 25 mg/kg Oral 
Single dose per 
day for 10 days 
4 h and every day for 14 
days post-drug 
- 
THC effectively reduced BP to the same 
degree over the treatment period. 
Humans 
Karniol 1973 
[45] 
Compared the effects 
of 8-THC and 9-THC 
Human 
Healthy 
21 5–20 mg Inhale Pre-test Avrg. of 20 m post-drug 
C: HR:82; 
T:HR:85 
9-THC was twice as active as 8-THC in 
increasing HR and caused more 
subjective symptoms. 
Karniol 1975 
[46] 
Examined the 
interaction between 
THC and CBN 
Human 
Healthy 
5 (M) 25 mg Oral Pre-test 
50, 70 and 160 m 
post-drug 
- 
THC induced increase in HR and 
psychological effects. No change on 
THC effects when combined with CBN 
Zimmer 1976 
[47] 
Examined changes of 
somatic parameters 
post-THC 
Human 
Healthy 
36 250 µg/kg Oral Pre-test 
Pre-drug and 4 h 
post-drug 
C: HR:87.9, 
BP:127.5; 
T: HR:89, 
BP:123 
THC raised HR with no changes on 
other parameters including BP 
Haney 2007 
[48] 
Determined the 
effects of naltrexone 
in combination with 
THC 
Human 
Healthy 
21 (11 M 
& 10 F) 
2.5–10 mg Oral Pre-test 
Continues for 6 h 
post-drug 
- 
Naltrexone enhanced intoxication 
effects of THC; THC increased HR 
Beaumont 
2009 [21] 
Evaluated whether 
THC has inhibitory 
effect on transient 
esophageal sphincter 
Human 
Healthy 
18 (M) 
10 and 20 
mg 
Oral Pre-test 
Continues for 4 h 
post-drug 
C: HR:59; 
T: HR:59 
THC inhibited the increased induced 
meal transient esophageal sphincter 
relaxation. THC increased HR and 
decreased BP 
Klooker 2011 
[49] 
Assessed the effect of 
THC on rectal 
sensation 
Human 
Healthy and IBD 
10 and 12 
5 and 10 
mg 
Oral Pre-test 
Continues for 105 m 
post-drug 
- 
THC had no effect on rectal perception 
to distension. THC increased HR with 
no effect on BP 
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Abbreviations: BP: blood pressure, BF: Blood flow, C: control group, CB1: cannabinoid receptor 1, CBD: Cannabidiol, CBF: cerebral blood flow, CBN: cannabinol, CV: 
cardiovascular, D: THC treated group, F: females, G: gender, h: hour(s), HR: heart rate, , IBD: inflammatory bowel disease i.p.: intraperitoneal, i.v.: intravenous, M: males, 
m: minute(s), s.c.: Subcutaneous, T: treatment group, THC: ∆9-Tetrahydrocannabinol. ↑: increased, ↓: decreased. * Basal parameters values before intervention (i.e., 
anaesthetic agents or THC). The units of the parameters are HR: beats/m, BP: mmHg, BF: mL/m.
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2.1. Effect of THC Treatment on Haemodynamics 
2.1.1. Anaesthetised Animals 
Fifteen publications [19,23–36] assessed the effect of THC administration in three anaesthetised 
species (rats, dogs, and cats, n = 664). THC significantly reduced BP and HR after acute dosing (BP, 
MD −19.7 mmHg, 95%CI −26.16, −13.25, p < 0.00001; HR, MD −53.49 bpm, 95%CI −65.9, −41.07, p < 
0.00001, Figure 2A, B). A cross-species analysis revealed that THC responses in the three species 
were significantly different in both BP (p < 0.00001) and HR (p = 0.01) (Figure 2A,B), and acute THC 
significantly reduced BP in rats and cats, but not in anesthetised dogs (p = 0.18, Figure 2A). 
 
(A) 
Study or Subgroup
1.1.1 Rats
Adams (1976b) 0.1 mg/kg
Adams (1976b)0.3 mg/kg
Adams (1976b)1 mg/kg
Adams (1976b)3 mg/kg
Kawasaki (1980) Exp.1 (1 mg/kg)
Kawasaki (1980) Exp.1 (2 mg/kg)
Kawasaki (1980) Exp.1 (5 mg/kg)
Krowicki (1999)0.02  mg/kg
Krowicki (1999)0.2 mg/kg
Krowicki (1999)2 mg/kg
Siqueira (1979)1 mg/kg
Siqueira (1979)10 mg/kg
Siqueira (1979)2 mg/kg
Siqueira (1979)5 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 178.82; Chi² = 146.85, df = 13 (P < 0.00001); I² = 91%
Test for overall effect: Z = 2.16 (P = 0.03)
1.1.2 Dogs
Cavero (1972)  2.5 mg/kg
Cavero (1973) 39 µg/kg
Cavero (1973)2.5 mg/kg
Cavero (1973)312 µg/kg
Cavero (1974)2.5 mg/kg
Jandhyala (1976)  2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 275.84; Chi² = 50.85, df = 5 (P < 0.00001); I² = 90%
Test for overall effect: Z = 1.35 (P = 0.18)
1.1.3 Cats
Daskalopoulos (1975) Dias. 100 µg/kg
Daskalopoulos (1975) Dias. 30 µg/kg
Daskalopoulos (1975) Diast. 300 µg/kg
Daskalopoulos (1975) Syst. 100 µg/kg
Daskalopoulos (1975) Syst. 30 µg/kg
Daskalopoulos (1975) Syst. 300 µg/kg
McConnell (1978)0.1 mg/kg
McConnell (1978)0.5 mg/kg
McConnell (1978)1 mg/kg
McConnell (1978)1.5 mg/kg
McConnell (1978)2 mg/kg
Schmeling (1981) 2 mg/kg
Schmeling (1981)2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 239.96; Chi² = 28.10, df = 12 (P = 0.005); I² = 57%
Test for overall effect: Z = 7.62 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 262.35; Chi² = 329.15, df = 32 (P < 0.00001); I² = 90%
Test for overall effect: Z = 5.99 (P < 0.00001)
Test for subgroup differences: Chi² = 27.44, df = 2 (P < 0.00001), I² = 92.7%
Mean
71
81
69
72
-12.5
-10
-20
-3.3
-18.4
-34.5
-5
-12.5
-8.3
-25.8
60.8
-10
-35
0.24
60
103
88
100
50
117
137
81
72
65.3
73.3
61.7
61.8
86.1
43.3
SD
19.5
12.2
12.2
19.5
14.1
5.5
15.8
2.6
24.3
6.5
12.2
12
20.3
20.7
51.4
6.1
10.5
17.3
8.2
11.4
29.8
34.7
9.4
41.1
41.1
15.8
20
28.4
21.2
17.6
26.6
22.8
14.4
Total
6
6
6
6
8
5
10
6
7
8
5
4
6
9
92
5
6
5
6
4
3
29
10
10
10
10
10
10
4
4
4
4
4
9
9
98
219
Mean
71
78
70
73
-11
-11
-11
0
0
0
0.5
0.5
0.5
0.4
68.6
5.8
5.8
5.8
59.4
89
116
116
116
157
157
157
83
106.5
112.2
112
113.8
159.8
91
SD
10.3
10.3
10.3
17.3
1.5
1.5
1.5
2.4
2.4
2.4
5.8
5.8
5.8
3.6
18.8
0.9
0.9
0.9
6.4
10.7
20.7
20.7
20.7
25.9
25.9
25.9
14
26.8
16.6
18
9.4
16
12
Total
12
12
12
12
2
2
2
5
5
5
6
8
6
6
95
6
2
2
2
4
3
19
3
3
3
3
3
3
4
4
4
4
4
4
4
46
160
Weight
3.2%
3.7%
3.7%
3.1%
3.8%
4.0%
3.8%
4.1%
3.1%
4.0%
3.6%
3.6%
3.2%
3.5%
50.3%
1.3%
4.0%
3.8%
3.5%
3.7%
3.2%
19.5%
2.2%
2.1%
2.6%
1.7%
1.7%
2.1%
2.6%
1.7%
2.4%
2.6%
2.3%
2.8%
3.4%
30.2%
100.0%
IV, Random, 95% CI
0.00 [-16.66, 16.66]
3.00 [-8.37, 14.37]
-1.00 [-12.37, 10.37]
-1.00 [-19.42, 17.42]
-1.50 [-11.49, 8.49]
1.00 [-4.25, 6.25]
-9.00 [-19.01, 1.01]
-3.30 [-6.26, -0.34]
-18.40 [-36.52, -0.28]
-34.50 [-39.47, -29.53]
-5.50 [-17.16, 6.16]
-13.00 [-25.43, -0.57]
-8.80 [-25.69, 8.09]
-26.20 [-40.03, -12.37]
-8.50 [-16.22, -0.79]
-7.80 [-55.30, 39.70]
-15.80 [-20.84, -10.76]
-40.80 [-50.09, -31.51]
-5.56 [-19.46, 8.34]
0.60 [-9.59, 10.79]
14.00 [-3.69, 31.69]
-10.32 [-25.25, 4.62]
-28.00 [-57.83, 1.83]
-16.00 [-47.80, 15.80]
-66.00 [-90.14, -41.86]
-40.00 [-78.83, -1.17]
-20.00 [-58.83, 18.83]
-76.00 [-106.90, -45.10]
-11.00 [-34.92, 12.92]
-41.20 [-79.47, -2.93]
-38.90 [-65.29, -12.51]
-50.30 [-74.97, -25.63]
-52.00 [-79.65, -24.35]
-73.70 [-95.33, -52.07]
-47.70 [-62.76, -32.64]
-44.51 [-55.95, -33.06]
-19.70 [-26.16, -13.25]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces BP THC increases BP
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(B) 
Figure 2. Changes in (A) BP and (B) HR induced by acute THC dosing in anaesthetised animals. 
Chronic THC administration (7–35 days) tended to increase mesenteric, femoral, and renal BF  
(p = 0.05, Figure 3C) with no significant effect on HR or BP. Heterogeneity was statistically 
significant for BP and HR measurements after acute THC dosing (p < 0.00001; I2 = 90%) and for BP 
after chronic THC dosing (BP, p = 0.03, I2 = 72%). 
Study or Subgroup
1.5.1 Dogs
Cavero (1972)  2.5 mg/kg
Cavero (1973) 39 µg/kg
Cavero (1973)2.5 mg/kg
Cavero (1973)312 µg/kg
Cavero (1973b)2.5 mg/kg
Cavero (1973b)312 µg/kg
Cavero (1973b)39 µg/kg
Cavero (1973b)5 mg/kg
Cavero (1974)2.5 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 343.66; Chi² = 88.00, df = 8 (P < 0.00001); I² = 91%
Test for overall effect: Z = 4.49 (P < 0.00001)
1.5.2 Rats
Adams (1976b) 0.1 mg/kg
Adams (1976b)0.3 mg/kg
Adams (1976b)1 mg/kg
Adams (1976b)3 mg/kg
Estrada (1987)0.07 mg/kg
Estrada (1987)0.15 mg/kg
Estrada (1987)0.31 mg/kg
Estrada (1987)0.62 mg/kg
Estrada (1987)1.25 mg/kg
Estrada (1987)2.5 mg/kg
Estrada (1987)5 mg/kg
Kawasaki (1980) Exp.1 (1 mg/kg)
Kawasaki (1980) Exp.1 (2 mg/kg)
Kawasaki (1980) Exp.1 (5 mg/kg)
Krowicki (1999)0.02  mg/kg
Krowicki (1999)0.2 mg/kg
Krowicki (1999)2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 4101.95; Chi² = 168.59, df = 16 (P < 0.00001); I² = 91%
Test for overall effect: Z = 4.83 (P < 0.00001)
1.5.3 Cats
McConnell (1978)0.1 mg/kg
McConnell (1978)0.5 mg/kg
McConnell (1978)1 mg/kg
McConnell (1978)1.5 mg/kg
McConnell (1978)2 mg/kg
Schmeling (1981)2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 97.46; Chi² = 6.22, df = 5 (P = 0.29); I² = 20%
Test for overall effect: Z = 5.03 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 874.54; Chi² = 296.25, df = 31 (P < 0.00001); I² = 90%
Test for overall effect: Z = 8.45 (P < 0.00001)
Test for subgroup differences: Chi² = 9.18, df = 2 (P = 0.01), I² = 78.2%
Mean
130
-10
-42
-33
-45
-33.6
3.6
-50
137
292
289
293
304
326
290
291
269
236
178
208
-80
-140
-160
-4.6
-64.4
-57.7
158.7
187.5
140.6
162
142.5
172.5
SD
11.1
7.3
12
12.2
13.8
18.3
8.8
15.1
14
36.7
66.1
36.7
46.5
74.4
74.4
64
65.8
22.5
6.9
27.7
18.6
36.8
52.1
15.4
46.2
46.3
41.8
44.2
20.2
42.2
23.2
44.7
Total
5
6
4
6
5
6
6
6
4
48
6
6
6
6
3
3
3
3
3
3
3
8
5
10
5
5
8
86
4
4
4
4
4
9
29
163
Mean
155
1
1
1
5
5
5
5
146
298
308
327
324
370
370
370
370
370
370
370
20
20
20
-2.3
-2.3
-2.3
172.7
225
191.3
224
172
245
SD
14.6
1.4
1.4
1.4
3.6
3.6
3.6
3.6
14
31.1
41.5
45
76.2
31
31
31
31
31
31
31
18.6
18.6
18.6
4.6
4.6
4.6
27.6
30
34
28.8
17
18
Total
6
2
2
2
1
1
1
1
4
20
12
12
12
12
1
1
1
1
1
1
1
2
2
2
4
4
4
73
4
4
4
4
4
9
29
122
Weight
4.3%
4.5%
4.4%
4.5%
4.3%
4.3%
4.5%
4.3%
4.1%
39.2%
3.4%
2.3%
3.2%
2.3%
1.1%
1.1%
1.3%
1.2%
2.0%
2.2%
1.9%
3.7%
3.0%
3.0%
4.3%
3.1%
3.5%
42.6%
2.7%
2.5%
3.2%
2.6%
3.7%
3.5%
18.2%
100.0%
IV, Random, 95% CI
-25.00 [-40.20, -9.80]
-11.00 [-17.15, -4.85]
-43.00 [-54.92, -31.08]
-34.00 [-43.95, -24.05]
-50.00 [-64.00, -36.00]
-38.60 [-54.85, -22.35]
-1.40 [-11.37, 8.57]
-55.00 [-68.99, -41.01]
-9.00 [-28.40, 10.40]
-29.51 [-42.41, -16.62]
-6.00 [-40.23, 28.23]
-19.00 [-76.87, 38.87]
-34.00 [-72.87, 4.87]
-20.00 [-76.95, 36.95]
-44.00 [-147.82, 59.82]
-80.00 [-183.82, 23.82]
-79.00 [-173.53, 15.53]
-101.00 [-197.10, -4.90]
-134.00 [-199.88, -68.12]
-192.00 [-253.26, -130.74]
-162.00 [-230.37, -93.63]
-100.00 [-128.82, -71.18]
-160.00 [-201.29, -118.71]
-180.00 [-221.32, -138.68]
-2.30 [-16.53, 11.93]
-62.10 [-102.85, -21.35]
-55.40 [-87.80, -23.00]
-83.01 [-116.67, -49.34]
-14.00 [-63.09, 35.09]
-37.50 [-89.85, 14.85]
-50.70 [-89.46, -11.94]
-62.00 [-112.07, -11.93]
-29.50 [-57.69, -1.31]
-72.50 [-103.98, -41.02]
-45.72 [-63.54, -27.90]
-53.49 [-65.90, -41.07]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-200 -100 0 100 200
THC reduces HR THC increases HR
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(A) 
 
(B) 
 
(C) 
Figure 3. Changes in (A) blood pressure, (B) heart rate, and (C) blood flow (BF) induced by chronic 
THC dosing in anaesthetised animals. 
2.1.2. Conscious Animals 
Eight publications [20,22,23,37–41] assessed the effect of THC administration in five conscious 
species, including rats, bats, mice, rabbits, and monkeys (n = 170). THC significantly reduced BP and 
HR after acute dosing (BP, MD −12.3 mmHg, 95%CI −19.42, −5.18, p = 0.0007; HR, MD −30.05 bpm, 
95%CI −38.47, −21.64, p < 0.00001, Figure 4A,B), and significantly increased CBF in murine models of 
stroke (BF, MD 32.35%, 95%CI 23.81, 40.88, p < 0.00001, Figure 4C). A cross-species analysis revealed 
that acute THC did not affect BP in bats (p = 0.36) and rats (p = 0.11) (Figure 4B). Heterogeneity was 
statistically significant for BP and HR measurements after acute THC dosing (BP, p < 0.00001, I2 = 
83%; HR, p < 0.00001, I2 = 87%), but not in BF (p = 0.5, I2 = 0%). 
2.1.3. Conscious Animal Models of Stress or Hypertension 
Two publications [43,44] assessed the effect of THC administration on BP in hypertensive rats 
(n = 22), and one [42] in a rat model of stress (n = 30). Acute and chronic (4–10 days) THC dosing 
Study or Subgroup
3.1.1 Dogs
Jandhyala  (1976) D7 2 mg/kg
Jandhyala  (1978) D35 2 mg/kg
Jandhyala and Buckley (1977) D7 2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 306.61; Chi² = 7.17, df = 2 (P = 0.03); I² = 72%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI)
Heterogeneity: Tau² = 306.61; Chi² = 7.17, df = 2 (P = 0.03); I² = 72%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
Mean
142
107
110
SD
10.5
13.8
34.2
Total
3
8
8
19
19
Mean
180
113
121
SD
9.5
22
42.9
Total
3
8
8
19
19
Weight
40.0%
38.2%
21.9%
100.0%
100.0%
IV, Random, 95% CI
-38.00 [-54.02, -21.98]
-6.00 [-24.00, 12.00]
-11.00 [-49.02, 27.02]
-19.88 [-43.83, 4.06]
-19.88 [-43.83, 4.06]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces BP THC increases BP
Study or Subgroup
3.3.1 Dogs
Jandhyala  (1978) D35 2 mg/kg
Jandhyala and Buckley (1977) D7 2 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.77 (P = 0.08)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.77 (P = 0.08)
Test for subgroup differences: Not applicable
Mean
181
142
SD
28.2
17.5
Total
8
8
16
16
Mean
168
121
SD
3.3
42.9
Total
8
8
16
16
Weight
72.7%
27.3%
100.0%
100.0%
IV, Random, 95% CI
13.00 [-6.67, 32.67]
21.00 [-11.11, 53.11]
15.18 [-1.59, 31.96]
15.18 [-1.59, 31.96]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces HR THC increases HR
Study or Subgroup
3.6.1 Dogs
Jandhyala  (1978) D35  FBF
Jandhyala  (1978) D35  MBF
Jandhyala (1978) D35 RBF
Subtotal (95% CI)
Heterogeneity: Tau² = 111.13; Chi² = 2.74, df = 2 (P = 0.25); I² = 27%
Test for overall effect: Z = 1.93 (P = 0.05)
Total (95% CI)
Heterogeneity: Tau² = 111.13; Chi² = 2.74, df = 2 (P = 0.25); I² = 27%
Test for overall effect: Z = 1.93 (P = 0.05)
Test for subgroup differences: Not applicable
Mean
73
186
137
SD
11.5
17.3
30.2
Total
2
2
2
6
6
Mean
51
145
145
SD
12.7
18.3
14.4
Total
2
2
2
6
6
Weight
50.3%
30.3%
19.4%
100.0%
100.0%
IV, Random, 95% CI
22.00 [-1.74, 45.74]
41.00 [6.10, 75.90]
-8.00 [-54.37, 38.37]
21.95 [-0.38, 44.29]
21.95 [-0.38, 44.29]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces BF THC increases BF
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significantly reduced BP (acute THC, MD −61.37 mmHg, 95% CI –117.56, −5.17, p = 0.03, Figure 5A; 
chronic THC, MD −22.09 mmHg, 95% CI −30.61, −13.58, p < 0.00001, Figure 5B). Heterogeneity was 
statistically significant after acute dosing (p < 0.00001, I2 = 99%), but not after chronic dosing (p = 0.69, 
I2 = 0%). 
2.1.4. Human Studies 
Six publications [21,46–50] assessed the acute effect of THC administration on HR in humans  
(n = 150), no studies examined BP or BF. THC significantly increased HR after acute dosing (HR, MD 
8.16 bpm, 95% CI 4.99, 11.33, p < 0.00001, Figure 6). Heterogeneity was statistically significant  
(p < 0.00001; I2 = 76%). 
 
(A) 
 
(B) 
Study or Subgroup
1.9.1 Mice
Hayakawa (2007a) 10 mg/kg
Hayakawa (2007b) 10 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.46, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 7.32 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.46, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 7.32 (P < 0.00001)
Test for subgroup differences: Not applicable
Mean
50
45
SD
21.6
7.6
Total
3
3
6
6
Mean
8.4
14
SD
16.8
2.4
Total
4
4
8
8
Weight
8.4%
91.6%
100.0%
100.0%
IV, Random, 95% CI
41.60 [12.13, 71.07]
31.00 [22.08, 39.92]
31.89 [23.36, 40.42]
31.89 [23.36, 40.42]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
THC reduces BF THC increases BF
Study or Subgroup
1.2.1 Bats
(Brown 1974)100 mg/kg
(Brown 1974)200 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 48.32; Chi² = 2.34, df = 1 (P = 0.13); I² = 57%
Test for overall effect: Z = 0.91 (P = 0.36)
1.2.2 Rats
Kawasaki (1980) Exp.2 (4 mg/kg)
Kawasaki (1980) Exp.2 (6 mg/kg)
Kawasaki (1980) Exp.2 (8 mg/kg)
Williams (1973) Exp.1 Non-immbo20 mg/kg
Williams (1973) Exp.2  Non-immbo20 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 96.61; Chi² = 36.04, df = 4 (P < 0.00001); I² = 89%
Test for overall effect: Z = 2.82 (P = 0.005)
1.2.3 Mice
Hayakawa (2007a) 10 mg/kg
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.73 (P = 0.006)
Total (95% CI)
Heterogeneity: Tau² = 83.27; Chi² = 41.83, df = 7 (P < 0.00001); I² = 83%
Test for overall effect: Z = 3.39 (P = 0.0007)
Test for subgroup differences: Chi² = 2.18, df = 2 (P = 0.34), I² = 8.2%
Mean
95
82
-5
6
-8
109
101
68.4
SD
8
11.2
4.4
4.4
9.7
4.1
5.1
11.6
Total
4
4
8
5
5
6
3
3
22
5
5
35
Mean
95
95
5
5
5
132
123.6
88.8
SD
5
5
2.8
2.8
2.8
6.2
4.1
12
Total
2
2
4
2
2
2
3
3
12
5
5
21
Weight
11.8%
10.4%
22.2%
14.5%
14.5%
12.8%
13.0%
13.5%
68.3%
9.5%
9.5%
100.0%
IV, Random, 95% CI
0.00 [-10.46, 10.46]
-13.00 [-25.98, -0.02]
-5.91 [-18.60, 6.78]
-10.00 [-15.47, -4.53]
1.00 [-4.47, 6.47]
-13.00 [-21.68, -4.32]
-23.00 [-31.41, -14.59]
-22.60 [-30.00, -15.20]
-13.23 [-22.43, -4.04]
-20.40 [-35.03, -5.77]
-20.40 [-35.03, -5.77]
-12.30 [-19.42, -5.18]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
THC reduces BP THC increases BP
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(C) 
Figure 4. Changes in (A) BP, (B) HR, and (C) blood flow induced by acute THC dosing in conscious 
animals. 
 
(A) 
Study or Subgroup
1.6.1 Rats
Kawasaki (1980) Exp.2 (4 mg/kg)
Kawasaki (1980) Exp.2 (6 mg/kg)
Kawasaki (1980) Exp.2 (8 mg/kg)
Kaymakcalan and Sivil (1974) D1 10 mg/kg
Osgood and Howes (1977)0.5 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 1668.07; Chi² = 38.65, df = 4 (P < 0.00001); I² = 90%
Test for overall effect: Z = 2.27 (P = 0.02)
1.6.2 Rabbits
Borgen (1974)3 mg/kg
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.10 (P < 0.00001)
1.6.3 Bats
(Brown 1974)100 mg/kg
(Brown 1974)200 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 5.32 (P < 0.00001)
1.6.4 Monkeys
Matsuzaki (1987) 4 mg/kg
Matsuzaki (1987)0.4 mg/kg
Matsuzaki (1987)0.75 mg/kg
Matsuzaki (1987)1.5 mg/kg
Matsuzaki (1987)3 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 23.49; Chi² = 17.53, df = 4 (P = 0.002); I² = 77%
Test for overall effect: Z = 7.15 (P < 0.00001)
1.6.5 Mice
Hayakawa (2007a) 10 mg/kg
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.66 (P = 0.10)
Total (95% CI)
Heterogeneity: Tau² = 136.16; Chi² = 99.39, df = 13 (P < 0.00001); I² = 87%
Test for overall effect: Z = 7.00 (P < 0.00001)
Test for subgroup differences: Chi² = 44.77, df = 4 (P < 0.00001), I² = 91.1%
Mean
-60
-119
-76.6
477.5
25
145
36
37
-32.6
-17.5
-23.3
-29.2
-34.1
492.3
SD
29.5
29.5
16.1
15.8
17.1
30
13.8
41.2
0.8
4.1
4.1
3.2
2.4
36
Total
5
5
6
10
6
32
4
4
4
4
8
1
1
1
1
1
5
5
5
54
Mean
-20
-20
-20
531
15
255
135
135
-10
-10
-10
-10
-10
529.7
SD
28
28
28
23.7
17.3
20
31.6
31.6
0.8
0.8
0.8
0.8
0.8
35.1
Total
2
2
2
10
12
28
4
4
2
2
4
1
1
1
1
1
5
5
5
46
Weight
2.6%
2.6%
3.2%
8.5%
8.8%
25.8%
4.0%
4.0%
2.7%
1.7%
4.4%
13.4%
12.0%
12.0%
12.5%
12.9%
62.9%
2.9%
2.9%
100.0%
IV, Random, 95% CI
-40.00 [-86.63, 6.63]
-99.00 [-145.63, -52.37]
-56.60 [-97.49, -15.71]
-53.50 [-71.15, -35.85]
10.00 [-6.82, 26.82]
-45.29 [-84.36, -6.22]
-110.00 [-145.33, -74.67]
-110.00 [-145.33, -74.67]
-99.00 [-144.84, -53.16]
-98.00 [-157.57, -38.43]
-98.63 [-134.95, -62.30]
-22.60 [-24.82, -20.38]
-7.50 [-15.69, 0.69]
-13.30 [-21.49, -5.11]
-19.20 [-25.66, -12.74]
-24.10 [-29.06, -19.14]
-18.35 [-23.38, -13.32]
-37.40 [-81.47, 6.67]
-37.40 [-81.47, 6.67]
-30.05 [-38.47, -21.64]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces HR THC increases HR
Study or Subgroup
1.3.1 Rats
Birmingham (1973) D1 3mg/kg
Kosersky (1978) D1  25 mg/kg
Williams (1973) Exp.1 Immbo20 mg/kg
Williams (1973) Exp.2  Immbo20 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 3236.95; Chi² = 260.91, df = 3 (P < 0.00001); I² = 99%
Test for overall effect: Z = 2.14 (P = 0.03)
Total (95% CI)
Heterogeneity: Tau² = 3236.95; Chi² = 260.91, df = 3 (P < 0.00001); I² = 99%
Test for overall effect: Z = 2.14 (P = 0.03)
Test for subgroup differences: Not applicable
Mean
168.4
-53
111
15.8
SD
6.2
22
5.1
5.1
Total
5
6
3
3
17
17
Mean
197.2
0
148
141.8
SD
12.5
12.2
10.3
4.1
Total
5
6
3
3
17
17
Weight
25.1%
24.6%
25.0%
25.3%
100.0%
100.0%
IV, Random, 95% CI
-28.80 [-41.03, -16.57]
-53.00 [-73.13, -32.87]
-37.00 [-50.01, -23.99]
-126.00 [-133.40, -118.60]
-61.37 [-117.56, -5.19]
-61.37 [-117.56, -5.19]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces BP THC increases BP
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(B) 
Figure 5. Changes in BP induced by (A) acute and (B) chronic THC dosing in animal models of stress 
or hypertension. 
 
Figure 6. Changes in HR induced by acute THC dosing in humans. 
2.2. Dose–Response to THC 
Doses ranging from 0.0003 to 770 mg were used in different species. The animal analyses 
showed a trend in the reduction of BP with higher THC doses (p = 0.07), with no change in HR. In 
humans, THC caused dose-dependent tachycardia (p = 0.01) (Figure 7). 
 
Figure 7. The effect of different THC doses on haemodynamic responses in vivo. The mean difference 
(MD) in animals' blood pressure (BP, A), animals' heart rate (HR, B), or heart rate (in humans only) (p 
= 0.01) (HR, C) is plotted against the log dose (mg) for each study. Error bars represent 95% 
Study or Subgroup
3.4.1 Rats
Birmingham (1973) D7 3mg/kg
Kosersky (1978) D10  25 mg/kg
Williams (1973) Exp.1 D4 Immbo20 mg/kg
Williams (1973) Exp.2 D4  Immbo20 mg/kg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.48, df = 3 (P = 0.69); I² = 0%
Test for overall effect: Z = 5.09 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.48, df = 3 (P = 0.69); I² = 0%
Test for overall effect: Z = 5.09 (P < 0.00001)
Test for subgroup differences: Not applicable
Mean
164.2
-32
130
133
SD
9.3
17.1
8.3
13.5
Total
5
6
3
3
17
17
Mean
184.2
-1
148
152.4
SD
15.6
12.2
10.3
15.5
Total
5
6
3
3
17
17
Weight
28.6%
25.7%
32.3%
13.4%
100.0%
100.0%
IV, Random, 95% CI
-20.00 [-35.92, -4.08]
-31.00 [-47.81, -14.19]
-18.00 [-32.97, -3.03]
-19.40 [-42.66, 3.86]
-22.09 [-30.61, -13.58]
-22.09 [-30.61, -13.58]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
THC reduces BP THC increases BP
Study or Subgroup
Beaumont (2009)10 mg
Beaumont (2009)20 mg
Haney (2007)10 mg
Haney (2007)2.5 mg
Haney (2007)5 mg
Karinol (1973)10 mg
Karinol (1973)20 mg
Karinol (1973)5 mg
Karinol (1975)25 mg
Klooker (2011) G1 10 mg
Klooker (2011) G1 5 mg
Klooker (2011) G2 10 mg
Zimmer (1976) 250 µg/kg
Total (95% CI)
Heterogeneity: Tau² = 14.39; Chi² = 49.60, df = 12 (P < 0.00001); I² = 76%
Test for overall effect: Z = 5.05 (P < 0.00001)
Mean
71
75
73.9
71.5
72.3
28.6
51.5
19
90.6
70
73.7
78.7
14.5
SD
12.7
12
1.7
1.3
0.1
14.7
9.9
12.7
19.5
8.6
6.4
13.8
15.6
Total
18
9
3
3
3
4
4
5
5
3
3
5
24
89
Mean
63
63
69.4
69.4
69.4
8.3
8.3
8.3
80.6
65
65
67.5
-3.1
SD
3
3
1.2
1.2
1.2
7.9
7.9
7.9
19.9
8.6
8.6
5.5
17.9
Total
9
9
3
3
3
2
2
2
5
3
3
5
12
61
Weight
10.7%
8.3%
16.5%
16.9%
17.6%
2.6%
3.7%
3.4%
1.5%
4.1%
5.0%
4.5%
5.1%
100.0%
IV, Random, 95% CI
8.00 [1.81, 14.19]
12.00 [3.92, 20.08]
4.50 [2.15, 6.85]
2.10 [0.10, 4.10]
2.90 [1.54, 4.26]
20.30 [2.21, 38.39]
43.20 [28.57, 57.83]
10.70 [-4.91, 26.31]
10.00 [-14.42, 34.42]
5.00 [-8.76, 18.76]
8.70 [-3.43, 20.83]
11.20 [-1.82, 24.22]
17.60 [5.70, 29.50]
8.16 [4.99, 11.33]
THC Control Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
THC reduces HR THC increases HR
-3 -2 -1 0 1 2
-3 0 0
-2 0 0
-1 0 0
0
1 0 0
2 0 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
HR
L o g  d o s e  (m g )
M
e
a
n
 d
if
fe
re
n
c
e
-3 -2 -1 0 1 2 3 4
-1 0 0
-5 0
0
5 0
1 0 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
B P
L o g  d o s e  (m g )
M
e
a
n
 d
if
fe
re
n
c
e
0 .0 0 .5 1 .0 1 .5
-2 0
0
2 0
4 0
6 0
H R  (h u m a n s  o n ly )
M
e
a
n
 d
if
fe
re
n
c
e
L o g  d o s e  (m g )
A B C
 13 of 19 
 
confidence intervals (CI). Near-significant and significant dose-dependent effects on the blood 
pressure in animals (p = 0.07) and on the HR in humans (p = 0.01). 
2.3. Quality 
Among the 31 included publications, 6 publications used randomisation in their design and 
reported blinding assessment of outcome and measurements. Twenty publications assessed more 
than one outcome, 19 conducted dose–response relationships, 26 assessed a time window for 
intervention, 11 measured outcomes >24 h post-drug, and no publications provided incomplete data. 
There was no significant relationship between the quality score and any outcome (Spearman’s rho 
coefficient of BP 0.22, p = 0.09; HR 0.27, p = 0.07 and BF 0.58, p = 0.3). 
2.4. Publication Bias 
Egger’s test showed that bias was present in all studies except in studies in anaesthetised 
animals, conscious animals (p = 0.001), animal models of stress or hypertension (C) (p = 0.001), and 
humans (D) (p < 0.0001) (Appendix A, Figure A1). 
3. Discussion 
The aim of this study was to determine the effect of THC on haemodynamics in vivo in animals 
and cannabis-naïve humans. Our analysis has shown that an acute dosing of THC reduced BP and 
HR, and increased BF in animals of different models. Chronic dosing of THC tended to increase BF 
in anaesthetised animals and reduced BP in animal models of stress or hypertension. The data 
concerning the effects of THC in humans was limited to HR only, revealing a dose-dependent 
increase, suggesting further work is required to determine the full haemodynamic effects of acute 
and chronic THC administration in humans, especially given the different effects of THC on HR 
observed across species. 
Our meta-analysis showed that acute THC dosing in anaesthetised animals reduced BP and 
HR, while a subgroup analysis revealed that there was no effect on BP or HR of anaesthetised dogs. 
However, Cavero et al. (1972, 1973, 1974) reported that intravenous administration of THC induced 
hypotension and bradycardia in dogs anaesthetised with pentobarbital caused by a reduction in the 
cardiac output and venous return mediated by the autonomic system [19,25–27]. Similarly, 
Schmeling reported that the reduction in sympathetic activity induced by THC in cats may cause 
hypotension and bradycardia [34]. It is suggested that the vagus nerve and the sympathetic outflow 
play a role in these effects induced by THC [36] and can be inhibited by the administration of a CB1 
antagonist [51]. The administration of THC for seven days subcutaneously reduced the increase in 
HR induced by pentobarbital anaesthetic agent in dogs, suggesting that THC antagonises the 
pentobarbital effect on the parasympathetic system (inhibiting the vagal tone) [30]. In rats 
anesthetised with pentobarbital, hypotension was reported after the administration of THC [35]; on 
the contrary, hypertension was reported in rats anesthetised with urethane post-THC [36], 
suggesting that THC may act differently with different anaesthetic agents. These studies suggest that 
the effects of THC in anaesthetised animals (hypotension and bradycardia) are induced through a 
central mechanism via the activation of CB1 receptors. 
In conscious animals under normal conditions, THC caused a variety of effects: hypotension 
was observed in bats, an effect which may be related to a change in venous activity [20], whereas 
another study in rats reported that THC induced tachycardia and hypertension, which are centrally 
mediated by increasing the level of adrenaline in the circulation [22]. However, studies in rat models 
of stress and hypertension, showed that THC lowered BP effectively [42–44]. The mechanism of the 
antihypertensive effect of THC in these models still needs to be studied. 
Our meta-analysis in cannabis-naïve humans highlighted the limited number of studies 
investigating the effect of THC in humans (6 publications, n = 123 participants) with insufficient data 
to meta-analyse BP or regional BF. Studies in cannabis-naïve volunteers showed that the 
administration of THC orally or by inhalation caused tachycardia [46–49,52]. Tachycardia is also 
reported in humans after smoking cannabis [53–55] which may indicate that tachycardia induced 
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post-cannabis smoking is caused by THC. The increase in HR caused by THC can be inhibited by 
CB1 antagonism [56], suggesting that CB1 activation may play a role in the haemodynamic effect of 
THC in humans. A greater number of studies investigating the haemodynamic effect of THC and its 
mechanisms under normal and pathological conditions in humans are required. 
Several studies have reported that phytocannabinoids such as cannabidiol (CBD) may alter the 
effect of THC. For example, Borgen and Davis suggested that CBD may act as a potential antagonist 
of the THC effect on HR in rabbits and rats [38] and protects against some of the negative effects of 
THC in humans with potentially opposite effects on regional brain functions [57,58]. The 
combination of CBD and THC such as in Sativex®, a licenced agent for the symptomatic treatment of 
spasticity in multiple sclerosis, has shown that CBD inhibits the tachycardia effect induced by THC 
in humans [59]. 
Dose–response analyses showed a relationship between THC dose and effect size on BP, but not 
HR, in different animal models, and on human HR. Dose-dependent effects on BP were also 
observed post-THC in anaesthetized rats [24,36], cats [28], and dogs [26]. A dose of 100 and 200 mg 
caused a dose-dependent reduction on the BP of conscious bats, but not on HR [20]. HR 
dose-dependent reduction was reported in anaesthetized dogs [26,27] and conscious monkeys [39]. 
In human studies, doses between 2.5 and 25 mg were used. A dose-dependent increase in HR was 
observed in humans after oral THC administration of 5, 10, and 20 mg [21,49]. Over-intoxication has 
been reported after 20 mg of oral administration of THC in 5 of 21 healthy volunteers [48]. 
There are a number of limitations to consider in this analysis. First, the principal intention of 10 
of the included studies was not to assess the cardiovascular effects of THC administration; therefore, 
the data extracted through secondary haemodynamic outcomes in this meta-analysis is for 
hypothesis-generating purposes. Second, the results should be interpreted with caution because of 
the heterogeneity between studies in terms of THC dose, time, and route of administration; the 
responses to THC will clearly be dependent upon peak plasma concentration, which are not easily 
comparable across studies. Indeed, a significant statistical heterogeneity was observed in the 
majority of the meta-analyses. Third, only 6 out of 31 articles used randomisation and described a 
masked assessment of outcomes, factors that can influence the reported outcomes. However, we 
found no significant correlation between study quality and effect size in this review. 
In conclusion, this study has summarised the in vivo cardiovascular effects of THC 
administration. Our analysis demonstrates that THC acts differently according to species, causing 
tachycardia in humans, and bradycardia, hypotension, and an increase in regional BF in animals 
under different conditions. THC may be a potential future treatment for cardiovascular disorders, 
though its use as a single agent will be limited by CB1 mediated psychogenic side effects, events that 
could be counterbalanced with other agents such as CBD. Data from human studies using THC 
alone is limited to heart rate only, thereby further good quality, randomised, blinded studies 
investigating the haemodynamic effects of THC in humans should be considered. 
4. Materials and Methods 
4.1. Search Strategy 
All studies investigating the haemodynamic effects of THC (including BP, HR, and BF) were 
searched for (until April 2017) in Medline, EMBASE, and PubMed. Search keywords included: 
∆9-Tetrahydrocannabinol, Tetrahydrocannabinol, THC, Dronabinol, Marinol, Nabilone, Namisol, 
cardiovascular, blood pressure, systolic, diastolic, hypertension, hypotension, heart rate, 
tachycardia, bradycardia, blood flow, haemodynamic, vasodilation, vasorelaxation, and 
vasoconstriction. References from the included studies were also hand-searched. 
Prespecified inclusion and exclusion criteria were used to prevent bias; the studies had to be in 
vivo, assess haemodynamics (BP, HR or BF), be original articles, be controlled studies, and use 
cannabis-naïve participants. Therefore, the exclusion criteria were: in vitro studies, mixtures of 
∆9-THC with other cannabis extracts, studies investigating the interaction of THC with other drugs 
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or cannabinoids, studies not assessing haemodynamics (BP, HR, or BF), review articles, editorials, 
and uncontrolled studies. 
4.2. Data Acquisition 
Data on BP (mmHg), HR (beats per minute, bpm), and BF (% change from baseline or mL/min) 
were extracted from the included papers, and the changes in haemodynamics 2 h post-drug after 
acute THC dosing were used for the analyses. This time point was selected as the peak plasma time 
is between 30 min and 4 h after oral administration and it was the most common time point when 
haemodynamics were measured throughout the articles. If there were no measurements taken at this 
time point (2 h post-drug), the closest time point to 2 h was used for the analyses. In chronic studies, 
the measurements taken at the end of the studies were used for the analyses. If the exact number of 
animals used in each drug group was not available, the lowest number of animals within the range 
given was used for the experimental group (THC), and the highest number was used for the control 
group. If a crossover design was used in a study, the total number of humans was distributed 
equally to the two groups. Articles were excluded if data were not available. Grab application 
(version 1.5) was used to extract values from the figures given in published articles if no values were 
stated within the text. If the published articles used multiple groups (e.g., to assess dose-dependent 
effects) with one control group, then the number of humans or animals per control group was 
divided into the number of comparison groups. For the dose–response analysis, the total dose of the 
drug administrated up to the time when the haemodynamics was measured was used. 
4.3. Quality 
Eight-point criteria derived from Stroke Therapy Academic Industry Recommendations 
(STAIR) [60–62] and the Cochrane collaborations tool [63] were used to identify the risk of bias. Each 
of the following criteria was equal to 1 point: randomisation, blinding of outcome assessment, 
blinding of personnel and participant, assessment of more than one outcome, dose–response 
relationship, therapeutic time window, assessment of outcome > 24 h, and incomplete outcome data. 
4.4. Data Analysis 
The studies were divided into acute and chronic groups. The data from human and animal 
studies were analysed separately. The animals were divided into two groups, anaesthetised and 
conscious, as the autonomic nervous system may respond differently in the two conditions [64], then 
grouped before the analysis in normal and abnormal (i.e., models of stress or hypertension) models 
and then subgrouped by species (mice, rats, dogs, etc.). For the THC dose–response analysis, the 
data were grouped according to the endpoint (BP, HR, or BF), and then subgrouped according to the 
dose. The data from each group were analysed as forest plots using the Cochrane Review Manager 
software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014), and as funnel plots using Stata (StataCorp. 2009. Stata Statistical Software: Release 11. College 
Station, TX, USA). Funnel plot asymmetry (publication bias) was assessed by Egger’s test [65]. Stata 
was also used for meta-regression that described the relationship between THC dose and effect size. 
PRISM 7 (GraphPad, Software, La Jolla, CA, USA) was used to produce the figures of dose–
response. Since heterogeneity was expected between the study protocols (different species, models, 
dose, and time) random-effect models were used. The results of continuous data are expressed as 
mean difference (MD) with 95% confidence intervals (CIs). The studies were weighted by sample 
size, and statistical significance was set at p < 0.05. 
Author Contributions: T.J.E. and S.E.O. conceived and designed the experiments; S.R.S. and S.A.M. collected 
and analyzed the data; all authors wrote and revised the manuscript. 
Conflicts of Interest: The authors declare no conflict of interest. 
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(A) Anaesthetised animals (B) Conscious animals 
  
(C) Animal models of stress or hypertension (D) Humans 
Figure A1. Funnel plots for each outcome evaluating the publication bias. The standard error (SE) of 
the mean difference (MD) in haemodynamics (MD, y axis) for each study is plotted against its effect 
size (horizontal axis). There was significant bias in conscious animals (B) (p = 0.001), animal models of 
stress or hypertension (C) (p = 0.001), and humans (D) (p < 0.0001). No significant bias in 
anaesthetised animals (A). 
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